FR Doc E9-3650[Federal Register: February 20, 2009 (Volume
74, Number 33)] [Notices] [Page 7923-7924] From the Federal
Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20fe09-91]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall,
prior to issuing a registration under this section to a bulk
manufacturer of a controlled substance in schedule I or II, and
prior to issuing a regulation under 21
U.S.C. 952(a)(2)
authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of
the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal
Regulations (CFR), 1301.34(a), this is notice that on January
16, 2009, Supernus Pharmaceuticals, Inc., 1550 East Gude Drive,
Rockville, Maryland 20850, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as
[[Page 7924]]
an importer of the basic classes of controlled substances
listed in schedule II:
|
Drug
|
Schedule
|
|
Oxycodone (9143)
|
II
|
|
Morphine (9300)
|
II
|
The company plans to import controlled substances for
clinical trials and analytical testing.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of
controlled substances may file comments or objections to the
issuance of the proposed registration and may, at the same time,
file a written request for a hearing on such application
pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be
filed no later than March 23, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published
in the Federal Register on September 23, 1975, (40 FR 43745-46),
all applicants for registration to import a basic class of any
controlled substances in schedule I or II are, and will continue
to be, required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration
pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E9-3650 Filed 2-19-09; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).